-
Mashup Score: 0
A randomized phase 3 study designed to assess sacituzumab govitecan-hziy for treatment of previously treated metastatic non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.Sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) is a Trop-2-directed antibody-drug conjugate. The agent is approved for treatment of certain patients with
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1What is Sacituzumab Govitecan for? [2023] Latest breast c... - 1 year(s) ago
Insights on Breast Cancer Treatment: Yuan Yuan, MD’s Discussion on Sacituzumab Govitecan and Other Novel Treatments By Yuan Yuan, MD, MPH Today we’re gonna take this chance to review breast cancer immunotherapy and novel drug antibody conjugates. This is my disclosure, so. So let’s, when we talk about breast cancer …
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What is Sacituzumab Govitecan for? @YuanYuanMDPhD answers this and much more https://t.co/5V3ehCCaJZ @MOASC_Office @GileadOncology #breastcancer @CSCancerCenter @ImmunomedicsInc @BreastCancerOrg #Trodelvy #Immunotherapy https://t.co/2jhZB7GcAo
-
-
Mashup Score: 1
SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.The agent also exhibited a manageable safety profile, researchers reported at ASCO Genitourinary Cancers Symposium.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#GU23 Sacituzumab govitecan induces response in cisplatin-ineligible urothelial carcinoma. https://t.co/dLVJvGaV7E @YaleMed #Trodelvy @GileadSciences @ASCO #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 1
The FDA granted priority review to sacituzumab govitecan-hziy for treatment of certain patients with advanced breast cancer.The designation applies to use of the agent by adults with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA grants priority review to #Trodelvy for pretreated metastatic breast cancer. https://t.co/sDuuTJ22tE #breastcancer @GileadSciences #BreastCancerAwarenessMonth #HemOnc #Oncology #MedEd #MedTwitter
-
-
Mashup Score: 1
Sacituzumab govitecan (SG), a trophoblast cell surface antigen-2 (Trop-2)-directed antibody-drug conjugate, has demonstrated antitumor efficacy and acceptable tolerability in a phase I/II multicenter trial (NCT01631552) in patients with advanced epithelial cancers. This report summarizes the safety data from the overall safety population (OSP) and efficacy data, including additional disease…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Thanks to the #sacituzumab investigators & patients who participated in this important research that ultimately led to approval of @ImmunomedicsInc’ #trodelvy. Thanks to Dr. Goldenberg for your mentor ship. https://t.co/f9VVgztIoj https://t.co/MFAcDRO45R
-
-
Mashup Score: 0
Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (Trodelvy) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
TROPHY-U-01 results lead to accelerated approval of sacituzumab govitecan #Trodelvy for pretreated metastatic #UrothelialCarcinoma @DrScottTagawa @WeillCornell joins @CaPsurvivorship @NUFeinbergMed for a discussion on UroToday. #WatchNow > https://t.co/nePx3TkUFn @cornellGUcancer https://t.co/g0vm2JB6hx
-
-
Mashup Score: 1Another Player in Advanced Bladder Cancer - 3 year(s) ago
Accelerated FDA approval of sacituzumab govitecan after chemo, immunotherapy
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA expanded indications for #Trodelvy with an accelerated approval for previously treated advanced #bladdercancer. By @CBankheadMPT. #BCSM https://t.co/Zfi44XT2b2
-
-
Mashup Score: 0
Notable 2020 FDA drug approvals explained.
Source: MDLinxCategories: General Medicine News, Latest HeadlinesTweet-
Indications and contraindications of latest #FDA-approved #drugs https://t.co/ll3SwrLzCD #CDER #Rukobia #Trodelvy #Tabrecta
-
-
Mashup Score: 3Triple-Negative Breast Cancer Drug Receives Approval - 4 year(s) ago
The FDA has granted accelerated approval to a new drug for patients with metastatic triple–negative breast cancer.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The @US_FDA has granted accelerated approval to sacituzumab govitecan-hziy (#Trodelvy) for patients w metastatic triple–negative #breastcancer who have received at least 2 previous therapies https://t.co/7VQPgl3dTG
-
-
Mashup Score: 07 new FDA-approved drugs in 2020 | MDLinx - 4 year(s) ago
COVID-19 hasn’t slowed down the FDA–they’ve approved 16 new drugs already this year.
Source: MDLinxCategories: General Medicine News, Latest HeadlinesTweet-
7 new #FDA-approved #drugs in #2020 https://t.co/XJg6C0Whp3 #COVID-19 #Nexletol #Nexlizet #Trodelvy
-
A randomized phase 3 study designed to assess sacituzumab govitecan-hziy for treatment of previously treated metastatic non-small cell lung cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer. #Trodelvy Read more 👇 https://t.co/ZwcdCxb36i